MajorVitamin K antagonist anticoagulants×Non-steroidal anti-inflammatory drugs (NSAIDs)
Updated · Methodology
Mechanism
Ibuprofen, like other non-steroidal anti-inflammatory drugs (NSAIDs), reversibly inhibits platelet aggregation and function and prolongs bleeding time (ibuprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). NSAIDs may increase the effects of coumarin-type anticoagulants, and ibuprofen itself can cause gastrointestinal bleeding, ulceration and perforation (AEMPS). Acenocoumarol acts through vitamin K, which the liver needs for gamma-carboxylation of the prothrombin complex factors. With NSAIDs, the risk of bleeding on acenocoumarol rises, including gastrointestinal bleeding (acenocoumarol SmPCs, AEMPS). In short-term controlled studies ibuprofen did not significantly change prothrombin time in people taking coumarin-type anticoagulants, but bleeding has been reported with this combination (ibuprofen label, US Food and Drug Administration, FDA). In data for warfarin, warfarin and NSAIDs have a synergistic effect on the risk of serious gastrointestinal bleeding. The risk with both is higher than with either drug alone (FDA).
Symptoms
The main risk is bleeding, above all from the stomach and intestine. With non-steroidal anti-inflammatory drugs (NSAIDs), gastrointestinal bleeding, ulceration and perforation can occur at any time during treatment, with or without warning symptoms, and can be fatal (ibuprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk is higher with increasing doses, in older people and in people with a history of ulcer, especially if it was complicated by bleeding or perforation (AEMPS). Bleeding is the main sign of an excessive acenocoumarol effect. The most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, vomiting blood, gastrointestinal, uterine, nose and gum bleeding and bleeding into the joints (acenocoumarol SmPC, overdose section, AEMPS).
Management
The acenocoumarol summary of product characteristics (SmPC) generally advises against combining acenocoumarol with non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, unless this is strictly indicated (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the drugs are given together, use close and frequent coagulation checks with the international normalised ratio (INR), for example twice a week, including after ibuprofen is stopped (AEMPS). Use ibuprofen with particular caution with coumarin-type oral anticoagulants (ibuprofen SmPC, AEMPS), and monitor people taking anticoagulants carefully during ibuprofen treatment (ibuprofen label, US Food and Drug Administration, FDA). Giving the lowest effective dose of ibuprofen for the shortest time can reduce adverse reactions (AEMPS). In older people and people with a history of ulcer, start with the lowest dose. For them, the ibuprofen SmPC recommends gastric protection with misoprostol or a proton pump inhibitor. Consider such protection in people taking other drugs that raise the gastrointestinal risk (AEMPS). If gastrointestinal bleeding or ulceration occurs, stop ibuprofen at once (AEMPS). For significant bleeding, stop acenocoumarol and give vitamin K1 5–10 mg intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, overdose section, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Ibuprofeno (Neobrufen 400 mg) (nº registro 70030), secciones 4.3, 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 70030, revisión 02/2026, secciones 4.3, 4.4 y 4.5
- FDA: Ibuprofen tablets (ibuprofen) prescribing information (2026)– FDA, DailyMed, setid 8804564c-9e1b-43c1-8b58-fd6ace645f00 (Granules India), SPL 10/2026, Warnings: Renal Effects; Precautions: Drug Interactions
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9